Valeo Pharma CEO Steve Saviuk joined Steve Darling from Proactive to share news the company has reported their 2021 revenue numbers that show a very increase in revenue. The company saw record revenues in 2021 of $13.6 million, up 81% over 2020.
Saviuk telling Proactive its Q4-21 revenues of $3.4 million was up 53% over Q4-20. The key to this growth is Redesca, Enerzair Breezhaler and Atectura Breezhaler, launched during 2021 and will see full potential in 2022. Saviuk also provided an update on their Asthma therapies Enerzair Breezehaler and Atectura Breezhaler which have now been accepted for reimbursement in Ontario, Manitoba and New Brunswick.